Jump to navigation Jump to search
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Pharmacokinetic data
Elimination half-life5.2 ± 1.7 (range 0.4 to 5.5) minutes
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass355.861 g/mol
3D model (JSmol)

WikiDoc Resources for Amodiaquine


Most recent articles on Amodiaquine

Most cited articles on Amodiaquine

Review articles on Amodiaquine

Articles on Amodiaquine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Amodiaquine

Images of Amodiaquine

Photos of Amodiaquine

Podcasts & MP3s on Amodiaquine

Videos on Amodiaquine

Evidence Based Medicine

Cochrane Collaboration on Amodiaquine

Bandolier on Amodiaquine

TRIP on Amodiaquine

Clinical Trials

Ongoing Trials on Amodiaquine at Clinical

Trial results on Amodiaquine

Clinical Trials on Amodiaquine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Amodiaquine

NICE Guidance on Amodiaquine


FDA on Amodiaquine

CDC on Amodiaquine


Books on Amodiaquine


Amodiaquine in the news

Be alerted to news on Amodiaquine

News trends on Amodiaquine


Blogs on Amodiaquine


Definitions of Amodiaquine

Patient Resources / Community

Patient resources on Amodiaquine

Discussion groups on Amodiaquine

Patient Handouts on Amodiaquine

Directions to Hospitals Treating Amodiaquine

Risk calculators and risk factors for Amodiaquine

Healthcare Provider Resources

Symptoms of Amodiaquine

Causes & Risk Factors for Amodiaquine

Diagnostic studies for Amodiaquine

Treatment of Amodiaquine

Continuing Medical Education (CME)

CME Programs on Amodiaquine


Amodiaquine en Espanol

Amodiaquine en Francais


Amodiaquine in the Marketplace

Patents on Amodiaquine

Experimental / Informatics

List of terms related to Amodiaquine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Amodiaquine (trade names Camoquin, Flavoquine), a 4-aminoquinoline compound related to chloroquine, is used as an antimalarial and anti-inflammatory agent.

Amodiaquine has been shown to be more effective than chloroquine in treating chloroquine-resistant Plasmodium falciparum malaria infections and may afford more protection than chloroquine when used as weekly prophylaxis. Amodiaquine, like chloroquine, is generally well tolerated. Although licensed, this drug is not marketed in the United States, but is widely available in Africa. Its use, therefore, is probably more practicable in long-term visitors and persons who will reside in Africa.[1]

Amodiaquine is a histamine N-methyltransferase inhibitor.

It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.[2]

Medical uses

Amodiaquine has become an important drug in the combination therapy for malaria treatment in Africa.[3]


It is bioactivated hepatically to its primary metabolite, N-desethylamodiaquine, by the cytochrome p450 enzyme CYP2C8. Among amodiaquine users, several rare but serious side effects have been reported and linked to variants in the CYP2C8 alleles. CYP2C8*1 is characterized as the wild-type allele, which shows an acceptable safety profile, while CYP2C8*2, *3 and *4 all show a range of “poor metabolizer” phenotypes. People who are poor metabolizers of amodiaquine display lower treatment efficacy against malaria, as well as increased toxicity.[4] Several studies have been conducted to determine the prevalence of CYP2C8 alleles amongst malaria patients in East Africa, and have tentatively shown the variant alleles have significant prevalence in that population.[5] About 3.6% of the population studied showed high risk for a poor reaction to or reduced treatment outcomes when treated with amodiaquine. This information is useful in developing programs of pharmacovigilance in East Africa, and have important clinical considerations for prescribing antimalarial medications in regions with high CYP2C8 variant frequency.


Recent research suggests that amodiaquine targets malignant melanoma cells through induction of autophagic-lysosomal and proliferative blockade sensitizing cancer cells to starvation- and chemotherapy-induced cell death.[6]


  1. CDC recommendations for travel to areas with malaria
  2. "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
  3. Kerb, Reinhold; Fux; Morike; Kremsner; Gil; Gleiter; Schwab (2009). "Pharmacogenetics of antimalarial drugs: effect on metabolism and transport". Lancet Infectious Disease. 9 (12): 760–774. doi:10.1016/S1473-3099(09)70320-2.
  4. Elyazar, Iqbal; Hay, Baird (April 2011). "Malaria Distribution, Prevalence, Drug Resistance, and control in Indonesia". Advanced Parasitology. Advances in Parasitology. 74 (74): 41–175. doi:10.1016/B978-0-12-385897-9.00002-1. ISBN 9780123858979.
  5. Roederer, Mary; Mcleod, Juliano (2011). "Can pharmacogenetics improve malaria". Bulletin of World Health Organization. 89 (11): 838–845. doi:10.2471/BLT.11.087320.
  6. PMID 24113242 (PMID 24113242)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand